Novo Nordisk — Medicare Part D spending
Rank #2 by attributed Part D spend · 44 tracked drugs · CMS data year 2023
About $18,953,892,612 of Medicare Part D spending in 2023 is attributed to Novo Nordisk across the 44 of its drugs tracked here, ranking it #2 among manufacturers on this site. Its biggest Part D drug is Ozempic at $9,194,048,435. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Novo Nordisk drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/ozempic-semaglutide/">Ozempic</a> | Semaglutide | $9,194,048,435 | $355.90 | 1,464,468 | #2 |
| <a href="/drug/novolog-flexpen-insulin-aspart/">Novolog Flexpen</a> | Insulin Aspart | $1,875,605,627 | $38.82 | 588,526 | #23 |
| <a href="/drug/rybelsus-semaglutide/">Rybelsus</a> | Semaglutide | $1,665,906,943 | $32.41 | 285,693 | #30 |
| <a href="/drug/tresiba-flextouch-u-200-insulin-degludec/">Tresiba Flextouch U-200</a> | Insulin Degludec | $1,047,670,731 | $71.71 | 197,096 | #48 |
| <a href="/drug/levemir-flexpen-insulin-detemir/">Levemir Flexpen</a> | Insulin Detemir | $1,025,556,477 | $32.59 | 346,204 | #49 |
| <a href="/drug/victoza-3-pak-liraglutide/">Victoza 3-Pak</a> | Liraglutide | $1,004,635,145 | $126.95 | 142,213 | #51 |
| <a href="/drug/tresiba-flextouch-u-100-insulin-degludec/">Tresiba Flextouch U-100</a> | Insulin Degludec | $726,928,549 | $35.94 | 258,451 | #73 |
| <a href="/drug/novolog-insulin-aspart/">Novolog</a> | Insulin Aspart | $518,394,273 | $30.16 | 148,967 | #102 |
| <a href="/drug/novolog-mix-70-30-flexpen-insulin-aspart-prot-insuln-asp/">Novolog Mix 70-30 Flexpen</a> | Insulin Aspart Prot/Insuln Asp | $335,124,166 | $38.70 | 62,157 | #155 |
| <a href="/drug/victoza-2-pak-liraglutide/">Victoza 2-Pak</a> | Liraglutide | $317,213,565 | $126.64 | 83,777 | #159 |
| <a href="/drug/levemir-insulin-detemir/">Levemir</a> | Insulin Detemir | $287,253,250 | $32.63 | 90,227 | #169 |
| <a href="/drug/levemir-flextouch-insulin-detemir/">Levemir Flextouch</a> | Insulin Detemir | $184,280,489 | $32.54 | 183,748 | #242 |
| Novolin 70-30 | Insulin NPh Hum/Reg Insulin Hm | $112,846,649 | $13.53 | 51,680 | #364 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | $105,895,817 | $39.57 | 35,877 | #376 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | $91,415,961 | $86.56 | 12,906 | #425 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | $66,766,546 | $31.29 | 14,231 | #524 |
| Novolin 70-30 Flexpen | Insulin NPh Hum/Reg Insulin Hm | $66,661,197 | $18.00 | 32,324 | #525 |
| Insulin Aspart Flexpen | Insulin Aspart | $56,416,317 | $19.21 | 82,297 | #581 |
| Novolin N | Insulin NPh Human Isophane | $53,437,662 | $13.42 | 31,731 | #592 |
| Novolin R | Insulin Regular, Human | $37,170,815 | $13.80 | 34,189 | #709 |
| Tresiba | Insulin Degludec | $27,706,471 | $36.07 | 10,460 | #826 |
| Fiasp | Insulin Aspart (Niacinamide) | $23,960,286 | $30.54 | 5,559 | #892 |
| Novolin N Flexpen | Insulin NPh Human Isophane | $21,350,139 | $17.44 | 16,998 | #935 |
| Novolin R Flexpen | Insulin Regular, Human | $17,195,350 | $18.18 | 18,020 | #1015 |
| Insulin Aspart | Insulin Aspart | $16,847,560 | $15.00 | 25,052 | #1021 |
| Novolog Penfill | Insulin Aspart | $13,098,434 | $37.62 | 5,070 | #1127 |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | $11,651,991 | $18.08 | 8,679 | #1170 |
| Norditropin Flexpro | Somatropin | $11,093,988 | $998.09 | 701 | #1187 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | $10,989,854 | $0.87 | 30,433 | #1193 |
| Novofine 32 | Pen Needle, Diabetic | $8,163,872 | $0.60 | 38,794 | #1319 |
| Glucagen | Glucagon | $4,903,701 | $294.73 | 9,515 | #1503 |
| Insulin Degludec Pen (U-100) | Insulin Degludec | $3,771,381 | $12.39 | 12,367 | #1604 |
| Insulin Degludec Pen (U-200) | Insulin Degludec | $3,536,624 | $24.43 | 6,510 | #1627 |
| Vagifem | Estradiol | $3,277,770 | $21.15 | 2,346 | #1660 |
| Fiasp Penfill | Insulin Aspart (Niacinamide) | $1,637,027 | $37.78 | 661 | #1913 |
| Insulin Aspart Penfill | Insulin Aspart | $477,862 | $18.34 | 676 | #2375 |
| Novofine Plus | Pen Needle, Diabetic | $307,946 | $0.55 | 3,012 | #2510 |
| Wegovy | Semaglutide | $199,774 | $496.25 | 47 | #2625 |
| Insulin Degludec | Insulin Degludec | $174,359 | $12.58 | 600 | #2656 |
| Sogroya | Somapacitan-Beco | $163,197 | $1,130.11 | 28 | #2681 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does Novo Nordisk get?
In 2023, about $18,953,892,612 of Medicare Part D spending is attributed to Novo Nordisk across the 44 of its drugs tracked here. Its biggest is Ozempic at $9,194,048,435. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is Novo Nordisk's top Medicare Part D drug?
Among the drugs tracked here, Novo Nordisk's highest Part D spending in 2023 is Ozempic at $9,194,048,435 (national rank #2 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21